Showing 1921-1930 of 3314 results for "".
- Alcon Introduces Reusable Toric Lens with Launch of TOTAL30 for Astigmatismhttps://modernod.com/news/alcon-introduces-reusable-toric-lens-with-launch-of-total30-for-astigmatism/2481324/Alcon announced plans to launch TOTAL30 for Astigmatism, which the company calls the first-and-only reusable contact lens with water gradient material for astigmatic contact lens wearers. Using Alcon’s proprietary water gradient material, first introduced with DAILIES TOTAL1&
- Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosishttps://modernod.com/news/ocugen-announces-ocu400-receives-orphan-drug-designations-for-retinitis-pigmentosa-and-leber-congenital-amaurosis/2481300/Ocugen announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3)—for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). “Receiving orphan drug designation is
- Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue Hydration Boost Contact Lens Rehydrating Dropshttps://modernod.com/news/bausch-lomb-receives-510k-clearance-from-fda-for-biotrue-hydration-boost-contact-lens-rehydrating-drops/2481290/Bausch + Lomb announced that it has received 510(k) clearance from the FDA for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses. “We ar
- MediPrint Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Assethttps://modernod.com/news/mediprint-ophthalmics-announces-it-has-initiated-its-sight-2-phase-2b-clinical-study-for-its-lead-asset/2481231/MediPrint Ophthalmics announced it has initiated its SIGHT-2 dose-finding phase 2b study for its proprietary drug-eluting contact lens for glaucoma. This is the second study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating
- Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officerhttps://modernod.com/news/atsena-therapeutics-expands-leadership-team-with-appointment-of-lis-leiderman-md-mba-as-chief-financial-officer-and-chief-business-officer/2481229/Atsena Therapeutics announced the appointment of Elisabeth (Lis) Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer. Dr. Leiderman has more than 15 years of finance, business development and strategy experience in the life sciences industry, most recently with gene the
- CooperVision Adds SynergEyes to Expand Specialty Contact Lens Adoption in North Americahttps://modernod.com/news/coopervision-adds-synergeyes-to-expand-specialty-contact-lens-adoption-in-north-america/2481220/Deepening its commitment to expand specialty contact lens adoption in North America and worldwide, CooperVision has added
- Heru Makes Appointments to Its Executive Leadership Teamhttps://modernod.com/news/heru-makes-appointments-to-its-executive-leadership-team/2481210/Heru announced several key executive appointments across its leadership team and board of directors designed to strengthen the company’s commercial operation and support its next phase of growth. Fred Drasner has been appointed as Heru’s Chairman of the Board of
- Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Managementhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2481191/Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management. These orthokeratology (ortho-k) lenses are worn overnight for the control of myopia and are specifically designed to match a patient’s eye based on i
- Lenstec Rebrands its Newly Approved Multifocal IOL to ClearView 3https://modernod.com/news/lenstec-rebrands-its-newly-approved-multifocal-iol-to-clearview-3/2481174/Lenstec announced that it has rebranded its new multifocal IOL, the SBL-3, to the ClearView 3 to better describe the vision patients can expect with the new IOL, according to Lenstec. The IOL was approved by the FDA in July 2022. "Since approval, the ClearView
- Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Diseasehttps://modernod.com/news/ocuphire-pharma-hosting-key-opinion-leader-event-on-oral-apx3330-for-diabetic-eye-disease/2481159/Ocuphire Pharma announced that it will host a key opinion leader (KOL) webinar highlighting oral APX3330, its lead drug candidate for diabetic retinopathy (DR) and diabetic macular edema (DME), on Friday, October 14, 2022 at 11 am to 12:30 pm Eastern Time. The event will